Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose – response relationships

Bibliography

• Gaucher P. De l'epithelioma primitif de la rate, hypertrophie idiopathique de la rate sans leukemie. Dissertation, Paris; 1882
   Google Scholar
• Aghion E. La maladie de Gaucher dans l'enfance. Dissertation, Paris; 1934
   Google Scholar
• Brady RO, Kanfer JN, Shapiro D. Metabolism of glucocerebrosides. II. Evidence of an enzymatic deficiency in Gaucher's disease. Biochem Biophys Res Commun 1965;18:221-5
   PubMed Web of Science ®Google Scholar
• Patrick AD. Short communications: a deficiency of glucocerebrosidase in Gaucher's disease. Biochem J 1955;97:17C-18C
   Google Scholar
• Sidransky E. Gaucher disease: complexity in a ‘simple’ disorder. Mol Genet Metab 2004;83:6-15
   PubMed Web of Science ®Google Scholar
• Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997;10:657-89
   PubMed Web of Science ®Google Scholar
• Beutler E, Grabowski GA. Gaucher disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors, The metabolic and molecular bases of inherited disease, 8th edition. New York: McGraw – Hill; 2001 . p. 3635-68
   Google Scholar
• Beutler E, Nguyen NJ, Henneberger MW, Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet 1993;52:85-8
   PubMed Web of Science ®Google Scholar
• Zimran A, Gelbart T, Westwood B, High frequency of the Gaucher disease mutation at nucleotide 1226 among Ashkenazi Jews. Am J Hum Genet 1991;49:855-9
   PubMed Web of Science ®Google Scholar
• Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999;281:249-54
   PubMed Web of Science ®Google Scholar
• Grabowski GA. Gaucher disease: gene frequencies and genotype/phenotype correlations. Genet Test 1997;1:5-12
   PubMedGoogle Scholar
• Aerts JM, Donker-Koopman WE, Koot M, Deficient activity of glucocerebrosidase in urine from patients with type 1 Gaucher disease. Clin Chim Acta 1986;158:155-63
   PubMed Web of Science ®Google Scholar
• Daniels LB, Glew RH. beta-Glucosidase assays in the diagnosis of Gaucher's disease. Clin Chem 1982;28:569-77
   PubMed Web of Science ®Google Scholar
• de Fost M, Out TA, de Wilde FA, Immunoglobulin and free light chain abnormalities in Gaucher disease type I: data from an adult cohort of 63 patients and review of the literature. Ann Hematol 2008;87:439-49
   PubMed Web of Science ®Google Scholar
• Mizukami H, Mi Y, Wada R, Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage. J Clin Invest 2002;109:1215-21
   PubMed Web of Science ®Google Scholar
• Lachmann RH, Wight DG, Lomas DJ, Massive hepatic fibrosis in Gaucher's disease: clinico-pathological and radiological. features QJM 2000;93:237-44
   PubMedGoogle Scholar
• Mankin HJ, Rosenthal DI, Xavier R. Gaucher disease. New approaches to an ancient disease. J Bone Joint Surg Am 2001;83-A:748-62
   Google Scholar
• Mansberg R, Uren R, Howman-Giles R. An avascular crisis in Gaucher's disease. Clin Nucl Med 2000;25:297-8
   PubMedGoogle Scholar
• Mistry PK, Sirrs S, Chan A, Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy. Mol Genet Metab 2002;77:91-8
   PubMed Web of Science ®Google Scholar
• Roberts WC, Fredrickson DS. Gaucher's disease of the lung causing severe pulmonary hypertension with associated acute recurrent pericarditis. Circulation 1967;35:783-9
   PubMed Web of Science ®Google Scholar
• Smith RL, Hutchins GM, Sack GHJr, Ridolfi RL. Unusual cardiac, renal and pulmonary involvement in Gaucher's disease. Intersitial glucocerebroside accumulation, pulmonary hypertension and fatal bone marrow embolization. Am J Med 1978;65:352-60
   PubMedGoogle Scholar
• de Fost M, vom Dahl S, Weverling GJ, Increased incidence of cancer in adult Gaucher disease in Western Europe. Blood Cells Mol Dis 2006;36:53-8
   PubMed Web of Science ®Google Scholar
• Zimran A, Liphshitz I, Barchana M, Incidence of malignancies among patients with type I Gaucher disease from a single referral clinic. Blood Cells Mol Dis 2005;34:197-200
   PubMed Web of Science ®Google Scholar
• Neudorfer O, Giladi N, Elstein D, Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM 1996;89:691-4
   PubMed Web of Science ®Google Scholar
• Tayebi N, Callahan M, Madike V, Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol Genet Metab 2001;73:313-21
   PubMed Web of Science ®Google Scholar
• Weinreb NJ. Imiglucerase and its use for the treatment of Gaucher's disease. Expert Opin Pharmacother 2008;9:1987-2000
   PubMed Web of Science ®Google Scholar
• Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr Opin Neurol 1999;12:167-76
   PubMed Web of Science ®Google Scholar
• Fratantoni JC, Hall CW, Neufeld EF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968;162:570-2
   PubMed Web of Science ®Google Scholar
• Furbish FS, Steer CJ, Barranger JA, The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. Biochem Biophys Res Commun 1978;81:1047-53
   PubMed Web of Science ®Google Scholar
• Sly WS, Kaplan A, Achord DT, Receptor-mediated uptake of lysosomal enzymes. Prog Clin Biol Res 1978;23:547-51
   PubMedGoogle Scholar
• Barton NW, Brady RO, Dambrosia JM. Replacement therapy for inherited enzyme deficiency – macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464-70
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Barton NW, Pastores G, Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 1995;122:33-9
   PubMed Web of Science ®Google Scholar
• Cox T, Lachmann R, Hollak C, Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5
   PubMed Web of Science ®Google Scholar
• Kornhaber GJ, Tropak MB, Maegawa GH, Isofagomine induced stabilization of glucocerebrosidase. Chembiochem 2008;9:2643-9
   PubMedGoogle Scholar
• Enquist IB, Nilsson E, Ooka A, Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci USA 2006;103:13819-24
   PubMed Web of Science ®Google Scholar
• Scientific discussion for the approval of Cerezyme. Committee for Proprietary Medicinal Products, 2003. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Cerezyme/070697en6.pdf [Last accessed 17 July 2009]
   Google Scholar
• Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 2003;163:2093-101
   PubMed Web of Science ®Google Scholar
• Van Patten SM, Hughes H, Huff MR, Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 2007;17:467-78
   PubMedGoogle Scholar
• Sato Y, Beutler E. Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. J Clin Invest 1993;91:1909-17
   PubMed Web of Science ®Google Scholar
• Friedman B, Vaddi K, Preston C, A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 1999;93:2807-16
   PubMed Web of Science ®Google Scholar
• Mistry PK, Wraight EP, Cox TM. Therapeutic delivery of proteins to macrophages: implications for treatment of Gaucher's disease. Lancet 1996;348:1555-9
   PubMed Web of Science ®Google Scholar
• Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 1999;93:2081-8
   PubMed Web of Science ®Google Scholar
• Ponce E, Moskovitz J, Grabowski G. Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase. Blood 1997;90:43-8
   PubMed Web of Science ®Google Scholar
• Zhao H, Bailey LA, Grabowski GA. Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies. Blood Cells Mol Dis 2003;30:90-6
   PubMed Web of Science ®Google Scholar
• Milligan A, Hughes D, Goodwin S, Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 2006;15:330-3
   PubMedGoogle Scholar
• Zimran A, Hollak CE, Abrahamov A, Home treatment with intravenous enzyme replacement therapy for Gaucher disease: an international collaborative study of 33 patients. Blood 1993;82:1107-9
   PubMed Web of Science ®Google Scholar
• Barton NW, Furbish FS, Murray GJ, Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 1990;87:1913-16
   PubMed Web of Science ®Google Scholar
• Figueroa ML, Rosenbloom BE, Kay AC, A less costly regimen of alglucerase to treat Gaucher's disease. N Engl J Med 1992;327:1632-6
   PubMed Web of Science ®Google Scholar
• Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993;82:408-16
   PubMed Web of Science ®Google Scholar
• Zimran A, Elstein D, Kannai R, Low-dose enzyme replacement therapy for Gaucher's disease: effects of age, sex, genotype, and clinical features on response to treatment. Am J Med 1994;97:3-13
   PubMed Web of Science ®Google Scholar
• Hollak CE, Aerts JM, Goudsmit R, Individualised low-dose alglucerase therapy for type 1 Gaucher's disease. Lancet 1995;345:1474-8
   PubMed Web of Science ®Google Scholar
• Andersson H, Kaplan P, Kacena K, Yee J. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Pediatrics 2008;122:1182-90
   PubMed Web of Science ®Google Scholar
• Charrow J, Andersson HC, Kaplan P, Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 2004;144:112-20
   PubMed Web of Science ®Google Scholar
• Mistry PK, Davies S, Corfield A, Successful treatment of bone marrow failure in Gaucher's disease with low-dose modified glucocerebrosidase. QJM 1992;83:541-6
   PubMed Web of Science ®Google Scholar
• Weinreb NJ, Charrow J, Andersson HC, Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 2002;113:112-19
   PubMed Web of Science ®Google Scholar
• Zimran A, Hadas-Halpern I, Zevin S, Low-dose high-frequency enzyme replacement therapy for very young children with severe Gaucher disease. Br J Haematol 1993;85:783-6
   PubMed Web of Science ®Google Scholar
• Zimran A, Elstein D, Levy-Lahad E, Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 1995;345:1479-80
   PubMed Web of Science ®Google Scholar
• Maas M, Hollak CE, Akkerman EM, Quantification of skeletal involvement in adults with type I Gaucher's disease: fat fraction measured by Dixon quantitative chemical shift imaging as a valid parameter. AJR Am J Roentgenol 2002;179:961-5
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll L, Di Rocco M, Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients. Curr Med Res Opin 2006;22:1045-64
   PubMed Web of Science ®Google Scholar
• Aerts JM, Hollak CE, van Breemen M, Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl 2005;94:43-6
   PubMedGoogle Scholar
• Hollak CE, van Weely S, van Oers MH, Aerts JM. Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease. J Clin Invest 1994;93:1288-92
   PubMed Web of Science ®Google Scholar
• Boot RG, Renkema GH, Strijland A, Cloning of a cDNA encoding chitotriosidase, a human chitinase produced by macrophages. J Biol Chem 1995;270:26252-6
   PubMed Web of Science ®Google Scholar
• Hollak CE, Maas M, Aerts JM. Clinically relevant therapeutic endpoints in type I Gaucher disease. J Inherit Metab Dis 2001;24(Suppl 2):97-105
   PubMedGoogle Scholar
• Boot RG, Verhoek M, de Fost M, Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood 2004;103:33-9
   PubMed Web of Science ®Google Scholar
• Moran MT, Schofield JP, Hayman AR, Pathologic gene expression in Gaucher disease: up-regulation of cysteine proteinases including osteoclastic cathepsin K. Blood 2000;96:1969-78
   PubMed Web of Science ®Google Scholar
• van Breemen MJ, de Fost M, Voerman JS, Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta 2007;1772:788-96
   PubMed Web of Science ®Google Scholar
• Beutler E. Enzyme replacement therapy for Gaucher's disease. Baillieres Clin Haematol 1997;10:751-63
   PubMedGoogle Scholar
• Altarescu G, Schiffmann R, Parker CC, Comparative efficacy of dose regimens in enzyme replacement therapy of type I Gaucher disease. Blood Cells Mol Dis 2000;26:285-90
   PubMed Web of Science ®Google Scholar
• de Fost M, Hollak CE, Groener JE, Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006;108:830-5
   PubMed Web of Science ®Google Scholar
• Wenstrup RJ, Kacena KA, Kaplan P, Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease. J Bone Miner Res 2007;22:119-26
   PubMed Web of Science ®Google Scholar
• Grabowski GA, Kacena K, Cole JA, Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Genet Med 2009;11:92-100
   PubMed Web of Science ®Google Scholar
• Sidransky E, Pastores GM, Mori M. Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser? Genet Med 2009;11:90-1
   PubMed Web of Science ®Google Scholar
• Pastores GM, Weinreb NJ, Aerts H, Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4-14
   PubMed Web of Science ®Google Scholar
• Damiano AM, Pastores GM, Ware JE Jr The health-related quality of life of adults with Gaucher's disease receiving enzyme replacement therapy. results from a retrospective study. Qual Life Res 1998;7:373-86
   PubMed Web of Science ®Google Scholar
• Giraldo P, Solano V, Perez-Calvo JI, Quality of life related to type 1 Gaucher disease: Spanish experience. Qual Life Res 2005;14:453-62
   PubMed Web of Science ®Google Scholar
• Masek BJ, Sims KB, Bove CM, Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 1999;8:263-8
   PubMed Web of Science ®Google Scholar
• Weinreb N, Barranger J, Packman S, Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 2007;71:576-88
   PubMed Web of Science ®Google Scholar
• Weinreb N, Taylor J, Cox T, A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase. Am J Hematol 2008;83:890-5
   PubMed Web of Science ®Google Scholar
• Andersson HC, Charrow J, Kaplan P, Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med 2005;7:105-10
   PubMed Web of Science ®Google Scholar
• Cox TM, Aerts JM, Belmatoug N, Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008;31:319-36
   PubMed Web of Science ®Google Scholar
• de Fost M, van Noesel CJ, Aerts JM, Persistent bone disease in adult type 1 Gaucher disease despite increasing doses of enzyme replacement therapy. Haematologica 2008;93:1119-20
   PubMed Web of Science ®Google Scholar
• Brunel-Guitton C, Rivard GE, Galipeau J, Enzyme replacement therapy in pediatric patients with Gaucher disease: what should we use as maintenance dosage? Mol Genet Metab 2009;96:73-6
   PubMed Web of Science ®Google Scholar
• Ida H, Rennert OM, Kobayashi M, Eto Y. Effects of enzyme replacement therapy in thirteen Japanese paediatric patients with Gaucher disease. Eur J Pediatr 2001;160:21-5
   PubMedGoogle Scholar
• de Fost M, Aerts JM, Groener JE, Low frequency maintenance therapy with imiglucerase in adult type I Gaucher disease: a prospective randomized controlled trial. Haematologica 2007;92:215-21
   PubMed Web of Science ®Google Scholar
• Kishnani PS, DiRocco M, Kaplan P, A randomized trial comparing the efficacy and safety of imiglucerase (Cerezyme) infusions every 4 weeks versus every 2 weeks in the maintenance therapy of adult patients with Gaucher disease type 1. Mol Genet Metab 2009;96:164-70
   PubMed Web of Science ®Google Scholar
• Elstein D, Abrahamov A, Hadas-Halpern I, Zimran A. Withdrawal of enzyme replacement therapy in Gaucher's disease. Br J Haematol 2000;110:488-92
   PubMed Web of Science ®Google Scholar
• vom Dahl S, Poll LW, Haussinger D. Clinical monitoring after cessation of enzyme replacement therapy in M. Gaucher. Br J Haematol 2001;113:1084-7
   PubMed Web of Science ®Google Scholar
• Grinzaid KA, Geller E, Hanna SL, Elsas LJ. Cessation of enzyme replacement therapy in Gaucher disease. Genet Med 2002;4:427-33
   PubMed Web of Science ®Google Scholar
• Drelichman G, Ponce E, Basack N, Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr 2007;151:197-201
   PubMed Web of Science ®Google Scholar
• Taddei TH, Kacena KA, Yang M, The underrecognized progressive nature of N370S Gaucher disease and assessment of cancer risk in 403 patients. Am J Hematol 2009;84:208-14
   PubMed Web of Science ®Google Scholar